Protein kinase Ce{open};-calcineurin cosignaling downstream of toll-like receptor 4 downregulates fibrosis and induces wound healing gene expression in cardiac myofibroblasts

Molecular and Cellular Biology

Volumn 34, Issue 4, 2014, Pages 574-594

  Mesquita, Rui F D S ^a   Paul, Margaret A ^a   Valmaseda, Aida ^b,c   Francois, Asvi ^a   Jabr, Rita ^a,f   Anjum, Shahzia ^d   Marber, Michael S ^a   Budhram Mahadeo, Vishwanie ^e   Heads, Richard J ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c University of Pompeu Fabra   (Spain)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; COLLAGEN; COLLAGEN 11A1; COLLAGEN 12A1; COLLAGEN 14A1; COLLAGEN 1A1; COLLAGEN 3A1; COLLAGEN 6A3; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; FIBRONECTIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C EPSILON; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FIBROBLAST; FIBROSIS; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; HEART MUSCLE CELL; HEART PROTECTION; MYOFIBROBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SITE DIRECTED MUTAGENESIS; UPREGULATION; WOUND HEALING; ANIMAL; GENETICS; HEART MUSCLE; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; CALCINEURIN; CELLS, CULTURED; CYCLOOXYGENASE 2; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; MICE; MYOCARDIUM; MYOFIBROBLASTS; PROTEIN KINASE C-EPSILON; RATS; TOLL-LIKE RECEPTOR 4; WOUND HEALING;

EID: 84892953008     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01098-13     Document Type: Article

References (69)

1. Jugdutt BI. 2003. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough. Circulation 108:1395-1403. http://dx.doi.org/10.1161/01.CIR.0000085658.98621.49.
2. Camelliti P, Devlin GP, Matthews KG, Kohl P, Green CR. 2004. Spatially and temporally distinct expression of fibroblast connexins after sheep ventricular infarction. Cardiovasc. Res. 62:415-425. http://dx.doi .org/10.1016/j.cardiores.2004.01.027.
3. Frantz S, Bauersachs J, Ertl G. 2009. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc. Res. 81:474-481. http://dx.doi.org/10.1093/cvr/cvn292.
4. Porter KE, Turner NA. 2009. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 123:255-278. http://dx.doi.org/10 .1016/j.pharmthera.2009.05.002.
5. Camelliti P, Borg TK, Kohl P. 2005. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65:40-51. http://dx.doi .org/10.1016/j.cardiores.2004.08.020.
6. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B. 2009. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat. Med. 15:774-780. http://dx.doi.org/10.1038/nm.1987.
7. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. 2005. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204:27-42. http://dx.doi.org/10.1111/j.0105 -2896.2005.00239.x.
8. Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H, Jayawardana ST, Ikeda S, Okumura K, Ogawa H. 2007. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. J. Leukoc. Biol. 82:657-665. http://dx.doi.org/10.1189/jlb.1206730.
9. You R, Zheng M, McKeown-Longo PJ. 2010. The first type III repeat in fibronectin activates an inflammatory pathway in dermal fibroblasts. J. Biol. Chem. 285:36255-36259. http://dx.doi.org/10.1074/jbc.C110.176990.
10. Brunn GJ, Bungum MK, Johnson GB, Platt JL. 2005. Conditional signaling by Toll-like receptor 4. FASEB J. 19:872-874. http://dx.doi.org /10.1096/fj.04-3211fje.
11. Frantz S, Ertl G, Bauersachs J. 2007. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 4:444-454. http://dx.doi.org/10.1038/ncpcardio0938.
12. Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG, Peters JH, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. 2011. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ. Res. 108:582-592. http://dx.doi.org/10.1161/CIRCRESAHA.110 .224428.
13. Li Y, Si R, Feng Y, Chen HH, Zou L, Wang E, Zhang M, Warren HS, Sosnovik DE, Chao W. 2011. Myocardial ischemia activates an injurious innate immune signaling via cardiac heat shock protein 60 and Toll-like receptor 4. J. Biol. Chem. 286:31308-31319. http://dx.doi.org/10.1074 /jbc.M111.246124.
14. Oyama J, Blais C, Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. 2004. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 109:784-789. http://dx.doi.org/10.1161/01 .CIR.0000112575.66565.84.
15. Ehrentraut H, Weber C, Ehrentraut S, Schwederski M, Boehm O, Knuefermann P, Meyer R, Baumgarten G. 2011. The Toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur. J. Heart Fail. 13:602-610. http://dx.doi.org/10.1093/eurjhf/hfr035.
16. Kim SC, Ghanem A, Stapel H, Tiemann K, Knuefermann P, Hoeft A, Meyer R, Grohe C, Knowlton AA, Baumgarten G. 2007. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol. 7:5. http://dx.doi.org/10.1186/1472-6793-7-5.
17. Reynolds CM, Suliman HB, Hollingsworth JW, Welty-Wolf KE, Carraway MS, Piantadosi CA. 2009. Nitric oxide synthase-2 induction optimizes cardiac mitochondrial biogenesis after endotoxemia. Free Radic. Biol. Med. 46:564-572. http://dx.doi.org/10.1016/j.freeradbiomed.2008 .11.007.
18. Riad A, Jager S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D, Karatas A, Heimesaat MM, Bereswill S, Dragun D, Pauschinger M, Schultheiss HP, Tschope C. 2008. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J. Immunol. 180:6954-6961.
19. Harrington LS, Belcher E, Moreno L, Carrier MJ, Mitchell JA. 2007. Homeostatic role of Toll-like receptor 4 in the endothelium and heart. J. Cardiovasc. Pharmacol. Ther. 12:322-326. http://dx.doi.org/10.1177 /1074248407306217.
20. Mellor H, Parker PJ. 1998. The extended protein kinase C superfamily. Biochem. J. 332:281-292.
21. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, Ping P. 2002. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon- MAPK interactions and differential MAPK activation in PKCepsiloninduced cardioprotection. Circ. Res. 90:390-397. http://dx.doi.org/10 .1161/01.RES.0000012702.90501.8D.
22. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R. 2004. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc. Res. 64:61-71. http://dx.doi.org/10.1016/j.cardiores.2004.05.011.
23. Faisal A, Saurin A, Gregory B, Foxwell B, Parker PJ. 2008. The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors. J. Biol. Chem. 283:18591-18600. http://dx.doi.org/10.1074/jbc.M710330200.
24. Dumont O, Mylroie H, Bauer A, Calay D, Sperone A, Thornton C, Hamdulay SS, Ali N, Boyle JJ, Choo JR, Samarel AM, Haskard DO, Randi AM, Evans PC, Mason JC. 2012. Protein kinase Cepsilon activity induces anti-inflammatory and anti-apoptotic genes via an ERK1/2- and NF-kappaB-dependent pathway to enhance vascular protection. Biochem. J. 447:193-204. http://dx.doi.org/10.1042/BJ20120574.
25. Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA, Tilley SL, Koller BH. 2006. COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 291:L144-156. http://dx.doi.org/10.1152/ajplung.00492.2005.
26. Iñiguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M. 2000. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J. Biol. Chem. 275:23627-23635. http://dx.doi.org/10.1074 /jbc.M001381200.
27. Werlen G, Jacinto E, Xia Y, Karin M. 1998. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J. 17:3101-3111. http://dx.doi.org/10.1093/emboj/17.11 .3101.
28. Hart SL, Arancibia-Carcamo CV, Wolfert MA, Mailhos C, O'Reilly NJ, Ali RR, Coutelle C, George AJ, Harbottle RP, Knight AM, Larkin DF, Levinsky RJ, Seymour LW, Thrasher AJ, Kinnon C. 1998. Lipidmediated enhancement of transfection by a nonviral integrin-targeting vector. Hum. Gene Ther. 9:575-585. http://dx.doi.org/10.1089/hum.1998 .9.4-575.
29. Gold LI, Schwimmer R, Quigley JP. 1989. Human plasma fibronectin as a substrate for human urokinase. Biochem. J. 262:529-534.
30. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. 1992. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357:692-694. http://dx.doi.org/10.1038/357692a0.
31. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228. http://dx.doi.org/10 .1016/S0092-8674(00)81573-1.
32. Castrillo A, Pennington DJ, Otto F, Parker PJ, Owen MJ, Bosca L. 2001. Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection. J. Exp. Med. 194:1231-1242. http://dx.doi.org /10.1084/jem.194.9.1231.
33. Ping P, Takano H, Zhang J, Tang XL, Qiu Y, Li RC, Banerjee S, Dawn B, Balafonova Z, Bolli R. 1999. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ. Res. 84:587-604. http://dx.doi.org/10.1161/01.RES.84.5.587.
34. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR, et al. 1995. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 92:1142-1146. http://dx.doi.org/10.1073 /pnas.92.4.1142.
35. Punn A, Mockridge JW, Farooqui S, Marber MS, Heads RJ. 2000. Sustained activation of p42/p44 mitogen-activated protein kinase during recovery from simulated ischaemia mediates adaptive cytoprotection in cardiomyocytes. Biochem. J. 350:891-899. http://dx.doi.org/10.1042 /0264-6021:3500891.
36. Obasanjo-Blackshire K, Mesquita R, Jabr RI, Molkentin JD, Hart SL, Marber MS, Xia Y, Heads RJ. 2006. Calcineurin regulates NFATdependent iNOS expression and protection of cardiomyocytes: cooperation with Src tyrosine kinase. Cardiovasc. Res. 71:672-683. http://dx .doi.org/10.1016/j.cardiores.2006.05.026.
37. Nicklin SA, Baker AH. 1999. Simple methods for preparing recombinant adenoviruses for high-efficiency transduction of vascular cells. Methods Mol. Med. 30:271-283.
38. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. 2006. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc. Res. 69:164-177. http://dx.doi.org/10.1016/j.cardiores.2005.08.017.
39. Esumi K, Nishida M, Shaw D, Smith TW, Marsh JD. 1991. NADH measurements in adult rat myocytes during simulated ischemia. Am. J. Physiol. 260:H1743-1752.
40. Pascussi JM, Busson-Le Coniat M, Maurel P, Vilarem MJ. 2003. Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol. Endocrinol. 17:42-55. http://dx.doi.org/10.1210 /me.2002-0244.
41. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW, II, Mochly-Rosen D. 2001. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc. Natl. Acad. Sci. U. S. A. 98:11114-11119. http://dx.doi.org/10.1073/pnas.191369098.
42. Cross HR, Murphy E, Bolli R, Ping P, Steenbergen C. 2002. Expression of activated PKC epsilon protects the ischemic heart, without attenuating ischemic H(+) production. J. Mol. Cell Cardiol. 34:361-367. http://dx .doi.org/10.1006/jmcc.2001.1518.
43. Lim HW, Molkentin JD. 1999. Calcineurin and human heart failure. Nat. Med. 5:246-247. http://dx.doi.org/10.1038/6430.
44. Somers JR, Beck PL, Lees-Miller JP, Roach D, Li Y, Guo J, Loken S, Zhan S, Semeniuk L, Duff HJ. 2008. iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin. Am. J. Physiol. Heart Circ. Physiol. 295:H1122-H1131. http://dx .doi.org/10.1152/ajpheart.00386.2008.
45. Urtreger AJ, Aguirre Ghiso JA, Werbajh SE, Puricelli LI, Muro AF, Bal de Kier Joff E. 1999. Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. Int. J. Cancer 82:748 -753. http://dx.doi.org/10.1002/(SICI)1097 -0215(19990827)82:5 748::AID-IJC203.0.CO;2-R.
46. Maqbool A, Hemmings KE, O'Regan DJ, Ball SG, Porter KE, Turner NA. 2013. Interleukin-1 has opposing effects on connective tissue growth factor and tenascin-C expression in human cardiac fibroblasts. Matrix Biol. 32:208-214. http://dx.doi.org/10.1016/j.matbio.2013.02.003.
47. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K. 1993. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res. Cardiol. 88(Suppl 1):107-124.
48. Yoshiyama M, Nakamura Y, Omura T, Izumi Y, Matsumoto R, Oda S, Takeuchi K, Kim S, Iwao H, Yoshikawa J. 2005. Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart 91: 1080-1085. http://dx.doi.org/10.1136/hrt.2004.035618.
49. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. 2009. Connective tissue growth factor and cardiac fibrosis. Acta Physiol. (Oxf) 195:321-338. http://dx.doi.org/10.1111/j .1748-1716.2008.01936.x.
50. Klein G, Schaefer A, Hilfiker-Kleiner D, Oppermann D, Shukla P, Quint A, Podewski E, Hilfiker A, Schroder F, Leitges M, Drexler H. 2005. Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. Circ. Res. 96:748-755. http://dx.doi.org/10.1161/01.RES .0000161999.86198.1e.
51. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. 2010. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur. J. Clin. Invest. 40:273-276. http://dx.doi.org/10.1111/j .1365-2362.2010.02258.x.
52. Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, Mak TW, Clifton MC, Strong RK, Ray P, Kolls JK. 2009. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J. Immunol. 182:4947-4956. http://dx.doi.org/10.4049/jimmunol.0803282.
53. Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. 2008. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol. Endocrinol. 22:1416-1426. http://dx.doi.org/10.1210 /me.2007-0420.
54. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thoren P, Hansson GK. 2006. Expression of neutrophil gelatinaseassociated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 26:136-142. http://dx.doi.org/10.1161/01.ATV .0000193567.88685.f4.
55. Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Froland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Oie E, Gullestad L, Aukrust P. 2009. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur. Heart J. 30:1229-1236. http://dx.doi.org/10 .1093/eurheartj/ehp088.
56. De Caterina R, Talmud PJ, Merlini PA, Foco L, Pastorino R, Altshuler D, Mauri F, Peyvandi F, Lina D, Kathiresan S, Bernardinelli L, Ardissino D. 2011. Strong association of the APOA5-1131TC gene variant and early-onset acute myocardial infarction. Atherosclerosis. 214:397-403. http://dx.doi.org/10.1016/j.atherosclerosis.2010.11.011.
57. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. 2007. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler. Thromb. Vasc. Biol. 27:1177-1183. http://dx.doi.org /10.1161/ATVBAHA.107.139352.
58. Valen G. 2011. Innate immunity and remodelling. Heart Fail. Rev. 16:71-78. http://dx.doi.org/10.1007/s10741-010-9187-1.
59. Ma S, Xiang J, Wu J, Hu B. 2003. Effects of lipoteichoic acid induced delayed preconditioning on ischemia-reperfusion injury in isolated rat hearts. J. Huazhong Univ. Sci. Technol. Med. Sci. 23:230-233. http://dx .doi.org/10.1007/BF02829499.
60. Tissier R, Berdeaux A, Ghaleh B, Couvreur N, Krieg T, Cohen MV, Downey JM. 2008. Making the heart resistant to infarction: how can we further decrease infarct size? Front. Biosci. 13:284-301. http://dx.doi.org /10.2741/2679.
61. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. 2001. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:3328-3333. http://dx.doi.org/10.1073/pnas.041614798.
62. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. 2013. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 10:15-26. http://dx.doi.org/10.1038/nrcardio .2012.158.
63. Doller A, Akool el-S, Huwiler A, Muller R, Radeke HH, Pfeilschifter J, Eberhardt W. 2008. Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol. Cell. Biol. 28:2608-2625. http://dx.doi.org/10.1128/MCB.01530-07.
64. Yuen CY, Wong SL, Lau CW, Tsang SY, Xu A, Zhu Z, Ng CF, Yao X, Kong SK, Lee HK, Huang Y. 2012. From skeleton to cytoskeleton: osteocalcin transforms vascular fibroblasts to myofibroblasts via angiotensin II and Toll-like receptor 4. Circ. Res. 111:e55-e66. http://dx.doi .org/10.1161/CIRCRESAHA.112.271361.
65. Shen W, Li Y, Tang Y, Cummins J, Huard J. 2005. NS-398, a cyclooxygenase- 2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis. Am. J. Pathol. 167:1105-1117. http: //dx.doi.org/10.1016/S0002-9440(10)61199-6.
66. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A. 2002. Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J. 16:1949-1951.
67. Leask A, Shi-Wen X, Khan K, Chen Y, Holmes A, Eastwood M, Denton CP, Black CM, Abraham DJ. 2008. Loss of protein kinase Cepsilon results in impaired cutaneous wound closure and myofibroblast function. J. Cell Sci. 121:3459-3467. http://dx.doi.org/10.1242/jcs.029215.
68. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD. 2003. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Invest. 111:1475-1486. http://dx.doi.org/10.1172/JCI200317295.
69. Manninen A, Renkema GH, Saksela K. 2000. Synergistic activation of NFAT by HIV-1 nef and the Ras/MAPK pathway. J. Biol. Chem. 275: 16513-16517. http://dx.doi.org/10.1074/jbc.M910032199.